Ranbaxy launches new products to mark World AIDS Day
Indian company Ranbaxy Laboratories has marked World AIDS Day, 1 December, with the introduction of two new anti-HIV products, Virolis-E and Virocomb-E, in India.
Indian company Ranbaxy Laboratories has marked World AIDS Day, 1 December, with the introduction of two new anti-HIV products, Virolis-E and Virocomb-E, in India.
Indicated for treatment of HIV-1 infection, both products contain three anti-retroviral drugs and are specifically designed to offer WHO (World Health Organisation) recommended 'first line Highly Active Anti-Retroviral Therapy' (HAART) in daily-use packs. In most countries outside India the products will be labelled and sold under the Coviro-E and Avocomb-E brand names respectively.
Virolis-E is a 'first of its kind product': a compliance pack containing two fixed dose combination tablets of Lamivudine 150mg and Stavudine 30/40mg and one tablet of Efavirenz 600mg. Virocomb-E, also a compliance pack, contains two fixed dose combination tablets of Lamivudine 150mg and Zidovudine 300mg and one tablet of Efavirenz 600mg.
The products are coded with what the company descirbes as 'easy to decipher graphics to indicate the time when drugs need to be consumed'; presentation which WHO encourages, as it is expected to enhance compliance with anti-HIV therapy.
Dr. Brian Tempest, ceo and md, said: 'We are pleased to introduce two innovative products that aim to make HIV treatment easier to administer and use. Ranbaxy is committed to HIV care and this is yet another step in our endeavour to make high quality, affordable and patient-friendly anti-retrovirals available worldwide.'